LTLuika A. Timmerman

Luika A. Timmerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luika A. Timmerman has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Adam J. Krieg

    Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR

    1 shared publication
  • Aras N. Mattis

    Affiliations UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States of America, Department of Pathology, University of California, San Francisco, San Francisco, California, United States of America, Liver Center, University of California, San Francisco, San Francisco, California, United States of America

    1 shared publication
  • Brian V. Lananna

    Department of Radiation Oncology, University of California, San Francisco, CA, 94115, USA

    1 shared publication
  • Carlos Corvera

    Affiliations Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States of America

    1 shared publication
  • Catherine Park

    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

    1 shared publication
  • David B. Donner

    Affiliations Department of Surgery, University of California, San Francisco, San Francisco, California, United States of America, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data

    by Noura Tbeileh, Luika Timmerman, Aras N. Mattis, Kan Toriguchi, Yosuke Kasai, Carlos Corvera, Eric Nakakura, Kenzo Hirose, David B. Donner, Robert S. Warren, et al.

    Tumors rich in stroma are associated with advanced stage and poor prognosis in colorectal adenocarcinoma (CRC). Abundance of stromal cells also has implications for genomic analysis of patient tumors as it may prevent detection of somatic mutations. As part of our efforts to interrogate stroma-cancer cell interactions and to identify actionable therapeutic targets in metastatic CRC, we aimed to determine the proportion of stroma embedded in hepatic CRC metastases by performing computational tumor purity analysis based on whole exome sequencing data (WES). Unlike previous studies focusing on histopathologically prescreened samples, we used an unbiased in-house collection of tumor specimens. WES from CRC liver metastasis samples were utilized to evaluate stromal content and to assess the performance of three in silico tumor purity tools, ABSOLUTE, Sequenza and PureCN. Matching tumor derived organoids were analyzed as a high purity control as they are enriched in cancer cells. Computational purity estimates were compared to those from a histopathological assessment conducted by a board-certified pathologist. According to all computational methods, metastatic specimens had a median tumor purity of 30% whereas the organoids were enriched for cancer cells with a median purity estimate of 94%. In line with this, variant allele frequencies (VAFs) of oncogenes and tumor suppressor genes were undetectable or low in most patient tumors, but higher in matching organoid cultures. Positive correlation was observed between VAFs and in silico tumor purity estimates. Sequenza and PureCN produced concordant results whereas ABSOLUTE yielded lower purity estimates for all samples. Our data shows that unbiased sample selection combined with molecular, computational, and histopathological tumor purity assessment is critical to determine the level of stroma embedded in metastatic colorectal adenocarcinoma.


  • Open Access

    xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction

    by Lara Cobler, Hui Zhang, Poojan Suri, Catherine Park, Luika A. Timmerman

    XCT inhibition sensitizes tumors to γ-radiation via glutathione reduction xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction


  • Open Access

    Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells

    by Mercè Padró, Raymond J. Louie, Brian V. Lananna, Adam J. Krieg, Luika A. Timmerman, Denise A. Chan

    About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is common and about 20% of resistant tumors loose ER-α expression via unknown mechanisms. Inhibition of ER-α loss could improve endocrine therapeutic efficacy, benefiting a significant number of patients. Here we test whether tumor hypoxia might commonly produce ER-α loss. Using standard molecular and cellular biological assays and a work station/incubator with controllable oxygen levels, we analyze the effects of hypoxia on ER-α protein, mRNA, and transcriptional activity in a panel of independently-derived ER-α positive cell lines. These lines were chosen to represent the diverse genetic backgrounds and mutations commonly present in ER-α positive tumors. Using shRNA-mediated knockdown and overexpression studies we also elucidate the role of hypoxia-inducible factor 1-alpha (HIF-1α) in the hypoxia-induced decrease in ER-α abundance. We present the first comprehensive overview of the effects of bona fide low environmental oxygen (hypoxia) and HIF-1α activity on ER-α abundance and transcriptional activity. We find that stabilized HIF-1α induces rapid loss of ER-α protein in all members of our diverse panel of breast cancer cell lines, which involves proteolysis rather than transcriptional repression. Reduced ER-α severely attenuates ER-α directed transcription, and inhibits cell proliferation without overt signs of cell death in the cell lines tested, despite their varying genomic backgrounds. These studies reveal a common hypoxia response that produces reduced ER-α expression and cell cycle stalling, and demonstrate a common role for HIF-1α in ER-α loss. We hypothesize that inhibitors of HIF-1α or the proteasome might stabilize ER-α expression in breast tumors in vivo, and work in combination with endocrine therapies to reduce resistance. Our data also suggests that disease re-occurrence in patients with ER-α positive tumors may arise from tumor cells chronically resident in hypoxic environments. We hypothesize that these non-proliferating cells may survive undetected until conditions change to oxygenate the environment, or cells eventually switch to proliferation via other signaling pathways.